Paid Clinical Trials and Focus Groups by Category |
|
|
|
Conditions: Influenza; Acute Lung Injury; Acute Respiratory Distress Syndrome
Intervention:
Sponsors: Institut National de la Santé Et de la Recherche Médicale, France; Assistance Publique - Hôpitaux de Paris; Institut Pasteur
Recruiting - verified March 2010
Condition: Viral Infections of the Upper Respiratory Tract
Interventions: Drug: Dexchlorpheniramine, pseudoephedrine, guaifenesin; Drug: Dexchlorpheniramine
Sponsor: Mantecorp Industria Quimica e Farmaceutica Ltd.
Not yet recruiting - verified March 2010
Condition: HIV Prevention
Intervention: Drug: Raltegravir
Sponsors: St Vincent's Hospital, Sydney; Merck
Not yet recruiting - verified March 2010
Condition: Dengue Virus
Interventions: Biological: Investigational Vaccine for DEN1; Other: Placebo injection
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified January 2010
Condition: Influenza A Virus, H5N1 Subtype
Interventions: Biological: VRC-AVIDNA036-00-VP; Biological: Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Condition: Influenza
Intervention:
Sponsor: QIAGEN Gaithersburg, Inc
Recruiting - verified March 2010
Condition: Pregnant Women With Peripartum Cardiomyopathy
Intervention:
Sponsors: University of Pittsburgh; National Institutes of Health (NIH)
Recruiting - verified March 2010
Condition: Influenza
Intervention: Biological: Inactivated Influenza A/H5N1/Indonesia/05/05 (clade 2)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified February 2010
Condition: HIV Infection
Intervention: Drug: Telmisartan
Sponsors: University of California, Los Angeles; California HIV/AIDS Research Program
Not yet recruiting - verified March 2010
Conditions: Influenza; Swine-origin A/H1N1 Influenza
Interventions: Biological: Swine A/H1N1 influenza vaccine (split virion, inactivated); Biological: Swine A/H1N1 influenza vaccine (split virion, inactivated)
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Condition: Hepatitis B Virus
Interventions: Drug: Peginterferon + Vitamin D; Drug: Peginterferon; Drug: Sebivo
Sponsor: Ziv Hospital
Not yet recruiting - verified March 2010
Condition: Hepatitis D, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: tenofovir; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Sting
Intervention: Other: Collection of the bedbugs and dermatological follow-up of the stings
Sponsor: Centre Hospitalier Universitaire de Nice
Recruiting - verified March 2010
Condition: Compensated Chronic Hepatitis B
Interventions: Drug: lamivudine; Drug: lamivudine; Drug: lamivudine, adefovir
Sponsors: Nanfang Hospital; Ministry of Health, China; GlaxoSmithKline
Recruiting - verified March 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron); Drug: Drug: SCH 900518 Biologic: Peginterferon alfa-2b; Drug: Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron); Drug: Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
Sponsor: Schering-Plough
Completed - verified March 2010
Condition: Chronic Hepatitis C Virus Infection
Interventions: Drug: telaprevir; Drug: VX-222; Drug: ribavirin; Biological: peginterferon-alfa-2a; Drug: VX-222
Sponsor: Vertex Pharmaceuticals Incorporated
Not yet recruiting - verified March 2010
Condition: Chronic Hepatitis B Virus, Pediatric
Interventions: Drug: Entecavir; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified March 2010
Condition: Seasonal Human Influenza
Interventions: Biological: GHB11L1; Biological: Placebo
Sponsor: AVIR Green Hills Biotechnology AG
Recruiting - verified March 2010
Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified March 2010
Conditions: Diphtheria; Haemophilus Influenzae Type b Disease; Pertussis; Poliomyelitis; Tetanus
Interventions: Biological: Infanrix Hib™; Biological: Infanrix-IPV/Hib™; Biological: Poliorix™
Sponsor: GlaxoSmithKline
Not yet recruiting - verified March 2010
Condition: Verruca Vulgaris
Interventions: Drug: Liquid nitrogen and cantharidin; Drug: Liquid nitrogen and topical placebo
Sponsor: North Idaho Dermatology
Completed - verified March 2010
Condition: Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Intervention: Biological: Serostim
Sponsor: EMD Serono
Completed - verified March 2010
Condition: Hepatitis B, Chronic
Interventions: Drug: peginterferon alfa-2a [PEGASYS]; Drug: peginterferon alfa-2a [PEGASYS]; Drug: Adefovir
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified March 2010
Condition: Herpes Zoster
Intervention: Biological: Herpes Zoster Vaccine GSK 1437173A
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: HIV; HIV Infections
Intervention:
Sponsor: George Washington University
Recruiting - verified March 2010
Condition: Influenza
Intervention: Biological: egg-derived A/H1N1 pandemic influenza vaccine
Sponsor: Opera Srl
Recruiting - verified March 2010
Condition: Human Immunodeficiency Virus
Intervention:
Sponsor: Abbott
Active, not recruiting - verified February 2010
Condition: Human Immunodeficiency Virus
Intervention: Drug: Lopinavir/Ritonavir (Kaletra)
Sponsor: Abbott
Active, not recruiting - verified March 2010
Condition: Human Immunodeficiency Virus
Intervention: Drug: Lopinavir/Ritonavir (Kaletra)
Sponsor: Abbott
Active, not recruiting - verified March 2010
Conditions: Fracture; Infection, Human Immunodeficiency Virus
Interventions: Other: No Antiretroviral (ARV) Drug Exposure; Drug: Any Antiretroviral (ARV) Drug Exposure
Sponsor: GlaxoSmithKline
Active, not recruiting - verified March 2010
Condition: Human Papillomavirus Infection
Interventions: Biological: Cervarix; Biological: Engerix-B
Sponsor: National Institute for Public Health and the Environment (RIVM)
Terminated - verified March 2010
Condition: Chronic Hepatitis C
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Device: autoinjector; Device: pre-filled syringe
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified March 2010
Condition: Premature Infants
Intervention:
Sponsors: Abbott; Assign Group Data Management Biostatistics
Recruiting - verified February 2010
Condition: Human Immunodeficiency Virus
Intervention:
Sponsor: Abbott
Recruiting - verified February 2010
Condition: Human Immunodeficiency Virus
Intervention: Drug: Lopinavir/Ritonavir (Kaletra)
Sponsor: Abbott
Active, not recruiting - verified February 2010
Condition: Metastatic Melanoma
Intervention: Other: TIL-Ad-INFg
Sponsor: Nantes University Hospital
Recruiting - verified March 2010
Condition: Influenza
Interventions: Drug: Chloroquine; Drug: Placebo
Sponsor: National University Hospital, Singapore
Active, not recruiting - verified February 2010
Condition: Human Immunodeficiency Virus
Intervention: Drug: lopinavir/ritonavir (Kaletra)
Sponsor: Abbott
Recruiting - verified February 2010
Condition: Peanut Allergy
Intervention: Other: Peanut flour
Sponsor: University of Texas Southwestern Medical Center
Enrolling by invitation - verified January 2010
Conditions: HIV Infection; Antiretroviral Side Effects; Lipodystrophy Syndrome Related to HIV Infection
Intervention: Device: Eutrophill
Sponsor: Assistance Publique - Hôpitaux de Paris
Completed - verified January 2010
Condition: Severe Respiratory Syncytial Virus Infection
Intervention:
Sponsor: Abbott
Completed - verified February 2010
Condition: Human Immunodeficiency Virus
Intervention: Drug: Lopinavir/Ritonavir (Kaletra)
Sponsor: Abbott
Active, not recruiting - verified March 2010
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)
Sponsor: GlaxoSmithKline
Active, not recruiting - verified February 2010
Conditions: Varicella; Herpes Zoster
Intervention:
Sponsor: Merck
Active, not recruiting - verified February 2010
Condition: Hepatitis C Recurrence
Intervention: Drug: Nitazoxanide
Sponsor: Mayo Clinic
Recruiting - verified February 2010
Condition: Dengue
Interventions: Biological: TetraVax-DV Vaccine-Admixture 1; Biological: TetraVax-DV Vaccine-Admixture 2; Biological: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health
Recruiting - verified February 2010
Condition: Dengue Virus
Interventions: Biological: Investigational Vaccine for Dengue Virus Subtype 2; Other: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Condition: Hepatitis C
Interventions: Drug: ABT-072; Drug: Placebo
Sponsors: Abbott; Abbott Japan Co.,Ltd
Not yet recruiting - verified February 2010
Condition: Cytomegalovirus Infections
Intervention:
Sponsor: Shaare Zedek Medical Center
Not yet recruiting - verified March 2010
Condition: Influenza A Virus/H5N1 Subtype
Intervention:
Sponsors: South East Asia Infectious Disease Clinical Research Network; University of Oxford; Wellcome Trust
Not yet recruiting - verified February 2010
Condition: HCV Infection
Interventions: Drug: GS-9256; Drug: GS-9190; Drug: Ribavirin
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Conditions: Acute on Chronic Liver Failure; Hepatitis B
Intervention: Drug: Tenofovir disoproxil fumarate (TDF)
Sponsor: Govind Ballabh Pant Hospital
Completed - verified October 2009
Condition: Hepatitis C, HCV, Chronic Hepatitis C, Hepatitis C Genotype 1
Interventions: Drug: ABT-450; Drug: ABT-072; Drug: ABT-333; Drug: ritonavir; Drug: pegIFN; Drug: ribavirin
Sponsor: Abbott
Not yet recruiting - verified February 2010
Condition: H1N1 2009 Influenza
Interventions: Biological: H1N1 2009 VLP Vaccine; Biological: H1N1 2009 VLP Vaccine; Biological: H1N1 2009 VLP Vaccine; Biological: Placebo
Sponsors: Novavax; Instituto Mexicano del Seguro Social
Active, not recruiting - verified March 2010
Condition: HIV Infections
Interventions: Biological: HIV-v (Low Dose); Biological: HIV-v (High Dose); Biological: HIV-v (Control)
Sponsor: PepTcell Limited
Recruiting - verified February 2010
Condition: Hepatitis C
Interventions: Biological: Ad6NSmut; AdCh3NSmut; Biological: Ad6NSmut; AdCh3NSmut; Biological: Ad6NSmut; AdCh3NSmut; Biological: Ad6NSmut; AdCh3NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: Ad6NSmut; AdCh3NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut
Sponsors: Okairos; University of Oxford
Recruiting - verified February 2010
Conditions: Alcohol Dependence; Problematic Drinking; Hazardous Drinking; Human Immunodeficiency Virus; Acquired Immunodeficiency Syndrome
Interventions: Drug: Vivitrol- Intramuscular naltrexone (depot-formulation); Drug: Placebo
Sponsors: Yale University; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Not yet recruiting - verified February 2010
Condition: Human Papillomavirus Infections
Intervention:
Sponsors: Merck; Danish Cancer Society; Icelandic Cancer Society; The Cancer Registry of Norway; Karolinska Institutet
Active, not recruiting - verified February 2010
Condition: Human Papillomavirus Infection
Intervention:
Sponsor: Merck
Active, not recruiting - verified February 2010
Conditions: CML; Adenovirus Infection
Intervention: Biological: Infusion of CTL lines
Sponsor: Baylor College of Medicine
Not yet recruiting - verified February 2010
Condition: Cytomegalovirus Infection
Interventions: Biological: Adoptive Cellular Therapy; Drug: Best available antiviral drug therapy
Sponsors: Cell Medica Ltd; Wellcome Trust; Choice Pharma Ltd; Commitum AB; BioAnaLab
Recruiting - verified February 2010
Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With T(15;17)(q22;q12); Adult Acute Myeloid Leukemia With T(16;16)(p13;q22); Adult Acute Myeloid Leukemia With T(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia; Blastic Phase Chronic Myelogenous Leukemia; Chronic Phase Chronic Myelogenous Leukemia; De Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Disease, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: plerixafor; Biological: filgrastim; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting - verified February 2010
Condition: Human Papillomavirus (HPV) Infections
Interventions: Biological: V503; Biological: Comparator: REPEVAX™ (Concomitant); Biological: Comparator: REPEVAX™ (Non-Concomitant)
Sponsor: Merck
Not yet recruiting - verified March 2010
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-Cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: everolimus; Drug: lenalidomide; Other: laboratory biomarker analysis; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Genetic: fluorescence in situ hybridization
Sponsor: Mayo Clinic
Not yet recruiting - verified February 2010
Conditions: Cryptococcal Meningitis; HIV Infections; AIDS
Interventions: Other: Early HIV Therapy Initiation; Other: Standard HIV Therapy Initiation
Sponsors: University of Minnesota - Clinical and Translational Science Institute; Makerere University; Mbarara University of Science and Technology; National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified February 2010
Conditions: HIV; HIV Infections
Intervention: Drug: darunavir/ritonavir then atazanavir/ritonavir
Sponsor: St Stephens Aids Trust
Not yet recruiting - verified February 2010
Condition: HIV-1 Infection
Intervention: Drug: Lopinavir/Ritonavir (Kaletra)
Sponsor: Abbott
Enrolling by invitation - verified March 2010
Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Elan Pharmaceuticals
Not yet recruiting - verified February 2010
Conditions: Bone Marrow; Bone Marrow Stromal Cells; Mesenchymal Stem Cells; Blood Donors
Intervention:
Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting - verified January 2010
Condition: Systemic Lupus Erythematosus (SLE)
Intervention: Drug: Vaccine
Sponsors: Assistance Publique - Hôpitaux de Paris; Institut National de la Santé Et de la Recherche Médicale, France
Completed - verified February 2010
Condition: HIV Infections
Interventions: Other: Dapivirine; Other: Placebo
Sponsor: International Partnership for Microbicides, Inc.
Not yet recruiting - verified February 2010
Condition: HIV Infection
Interventions: Biological: AGS-004; Biological: Placebo
Sponsor: Argos Therapeutics
Not yet recruiting - verified February 2010
Conditions: HIV; AIDS; HIV Infections
Intervention: Other: DOT-HAART
Sponsors: National Institute of Mental Health (NIMH); Brigham and Women's Hospital; Socios en Salud Sucursal, Lima, Peru; Harvard School of Public Health; Harvard University
Recruiting - verified February 2010
Condition: Minimal Hepatic Encephalopathy
Interventions: Drug: Rifaximin; Drug: rifaximin
Sponsors: Hunter Holmes Mcguire Veteran Affairs Medical Center; Salix Pharmaceuticals
Recruiting - verified February 2010
Conditions: Respiratory Tract Infections; Influenza
Interventions: Dietary Supplement: Cholecalciferol (Vitamin D/Vigantol oil); Dietary Supplement: Miglyol oil
Sponsors: Barts & The London NHS Trust; National Health Service, United Kingdom
Not yet recruiting - verified February 2010
Conditions: Chronic Fatigue Syndrome; Cognitive Impairments
Interventions: Drug: Lisdexamfetamine Dimesylate; Drug: Placebo Comparator: Sugar pill
Sponsors: Rochester Center for Behavioral Medicine; Shire Pharmaceutical Development
Recruiting - verified February 2010
Conditions: Liver Fibrosis; Liver Cirrhosis; Viral Hepatitis; Liver Tumour; Cardiac Failure; Biliary Cholestasis.
Interventions: Device: ARFI measurement; Device: ARFI measurement; Device: ARFI measurement
Sponsor: University Hospital, Bordeaux
Not yet recruiting - verified March 2010
Condition: Colorectal Neoplasms
Intervention:
Sponsor: Merck KGaA
Recruiting - verified March 2010
Condition: Community-Acquired Pneumonia
Intervention:
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Colorectal Neoplasms
Intervention: Drug: Erbitux (Cetuximab)
Sponsor: Merck KGaA
Recruiting - verified March 2010
Condition: Colorectal Neoplasm
Intervention: Drug: Cetuximab
Sponsor: Merck KGaA
Recruiting - verified February 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: Matching placebo; Drug: Otelixizumab
Sponsor: GlaxoSmithKline
Not yet recruiting - verified February 2010
Condition: Diabetes Mellitus, Type II
Intervention:
Sponsor: Postgraduate Institute of Medical Education and Research
Recruiting - verified January 2010
All Categories ... by Medical Condition » ... Viral Diseases 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
